Abstract
The expanding field of monoclonal antibody-based pharmaceuticals has triggered increased interest in analytical characterization of these large proteins and in understanding of their heterogeneity and degradation pathways. As a result, a large number of enzymatic modifications as well as chemical and physical degradations have been reported in monoclonal antibodies in recent years. Most heterogeneity is related to changes in the surface charge of the antibody, either directly, as a change in the number of charged residues, or indirectly as a chemical or physical alteration that changes surface-charge distribution. This review presents an overview of the sources of charge-related heterogeneity in monoclonal antibodies and the methods used for their detection. A detailed section is dedicated to deamidation of asparagine and isomerization of aspartic acid residues, two ubiquitous degradation pathways detected in antibodies and other proteins as well. Finally, kinetic modeling of the accumulation of antibody variants is presented as a tool to determine the expected fraction of molecules that have undergone one or more degradation reactions.
Keywords: Monoclonal antibody, charge heterogeneity, degradation, chromatography, deamidation, isomerization
Current Pharmaceutical Biotechnology
Title: Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
Volume: 9 Issue: 6
Author(s): J. Vlasak and R. Ionescu
Affiliation:
Keywords: Monoclonal antibody, charge heterogeneity, degradation, chromatography, deamidation, isomerization
Abstract: The expanding field of monoclonal antibody-based pharmaceuticals has triggered increased interest in analytical characterization of these large proteins and in understanding of their heterogeneity and degradation pathways. As a result, a large number of enzymatic modifications as well as chemical and physical degradations have been reported in monoclonal antibodies in recent years. Most heterogeneity is related to changes in the surface charge of the antibody, either directly, as a change in the number of charged residues, or indirectly as a chemical or physical alteration that changes surface-charge distribution. This review presents an overview of the sources of charge-related heterogeneity in monoclonal antibodies and the methods used for their detection. A detailed section is dedicated to deamidation of asparagine and isomerization of aspartic acid residues, two ubiquitous degradation pathways detected in antibodies and other proteins as well. Finally, kinetic modeling of the accumulation of antibody variants is presented as a tool to determine the expected fraction of molecules that have undergone one or more degradation reactions.
Export Options
About this article
Cite this article as:
Vlasak J. and Ionescu R., Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods, Current Pharmaceutical Biotechnology 2008; 9(6) . https://dx.doi.org/10.2174/138920108786786402
DOI https://dx.doi.org/10.2174/138920108786786402 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Natural and Induced Antibody Polyreactivity
Anti-Cancer Agents in Medicinal Chemistry Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry The Effect of Tumour Necrosis Factor-α on Periodontal Ligament Stem Cell Differentiation and the Related Signaling Pathways
Current Stem Cell Research & Therapy An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry Development and Validation of a Rapid and Sensitive Assay for Simultaneous Quantification of Lenalidomide and Dexamethasone in Human Plasma by Liquid Chromatography Coupled to Tandem Mass-Spectrometry
Current Pharmaceutical Analysis Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Current Topics in Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
Current Cancer Drug Targets Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Current Medicinal Chemistry Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives
Current Medicinal Chemistry Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry The ARRONAX Project
Current Radiopharmaceuticals Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets